"Paroxetine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serotonin uptake inhibitor that is effective in the treatment of depression.
| Descriptor ID |
D017374
|
| MeSH Number(s) |
D03.383.621.600
|
| Concept/Terms |
Paroxetine Hydrochloride- Paroxetine Hydrochloride
- Paroxetine Hydrochloride Hemihydrate
- Hemihydrate, Paroxetine Hydrochloride
- Hydrochloride Hemihydrate, Paroxetine
- Paroxetine Hydrochloride, Hemihydrate
- Hemihydrate Paroxetine Hydrochloride
- Hydrochloride, Hemihydrate Paroxetine
|
Below are MeSH descriptors whose meaning is more general than "Paroxetine".
Below are MeSH descriptors whose meaning is more specific than "Paroxetine".
This graph shows the total number of publications written about "Paroxetine" by people in this website by year, and whether "Paroxetine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 1 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Paroxetine" by people in Profiles.
-
Zeb F, Naqvi S, Rahman R, Farooq AD. Depressive symptoms, monoamines levels, MAO-B activity and effect of treatment in a subset of depressed individuals from government sector hospital at Karachi. Pak J Pharm Sci. 2017 Jul; 30(4(Suppl.)):1509-1519.
-
Fantasia HC. A Nonhormonal Treatment for Moderate to Severe Vasomotor Symptoms of Menopause. Nurs Womens Health. 2016 Oct - Nov; 20(5):511-518.
-
Yonkers KA, Blackwell KA, Glover J, Forray A. Antidepressant use in pregnant and postpartum women. Annu Rev Clin Psychol. 2014; 10:369-92.
-
Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand. 2013 Feb; 127(2):94-114.
-
Thal DM, Homan KT, Chen J, Wu EK, Hinkle PM, Huang ZM, Chuprun JK, Song J, Gao E, Cheung JY, Sklar LA, Koch WJ, Tesmer JJ. Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol. 2012 Nov 16; 7(11):1830-9.
-
Yonkers KA, Lin H, Howell HB, Heath AC, Cohen LS. Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine. J Clin Psychiatry. 2008 Apr; 69(4):659-65.
-
Jhee OH, Seo HK, Lee MH, Jeon YC, Shaw LM, Lee SH, Hur Y, Kim KH, Lee HS, Lee SE, Kang JS. Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. Arzneimittelforschung. 2007; 57(7):455-61.
-
Yonkers KA, Holthausen GA, Poschman K, Howell HB. Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol. 2006 Apr; 26(2):198-202.
-
Cohen LS, Soares CN, Yonkers KA, Bellew KM, Bridges IM, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med. 2004 Sep-Oct; 66(5):707-13.
-
Brunswick DJ, Goodman DB, O'Reardon JP, Chopra M, Amsterdam JD. Pindolol does not augment cortisol and prolactin responses to paroxetine in healthy subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2004 May; 28(3):477-80.